These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 10561327)

  • 1. Phase I trial to determine the safety, pharmacodynamics, and pharmacokinetics of RSR13, a novel radioenhancer, in newly diagnosed glioblastoma multiforme.
    Kleinberg L; Grossman SA; Piantadosi S; Pearlman J; Engelhard H; Lesser G; Ruffer J; Gerber M
    J Clin Oncol; 1999 Aug; 17(8):2593-603. PubMed ID: 10561327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
    Kleinberg L; Grossman SA; Carson K; Lesser G; O'Neill A; Pearlman J; Phillips P; Herman T; Gerber M
    J Clin Oncol; 2002 Jul; 20(14):3149-55. PubMed ID: 12118029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of RSR13, a radiation-enhancing hemoglobin modifier: tolerance of repeated intravenous doses and correlation of pharmacokinetics with pharmacodynamics.
    Kavanagh BD; Khandelwal SR; Schmidt-Ullrich RK; Roberts JD; Shaw EG; Pearlman AD; Venitz J; Dusenbery KE; Abraham DJ; Gerber MJ
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):1133-9. PubMed ID: 11240256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Allosteric modification of oxygen delivery by hemoglobin.
    Wahr JA; Gerber M; Venitz J; Baliga N
    Anesth Analg; 2001 Mar; 92(3):615-20. PubMed ID: 11226087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of RSR13, a synthetic allosteric modifier of hemoglobin, alone and in combination with dizocilpine, on outcome from transient focal cerebral ischemia in the rat.
    Sarraf-Yazdi S; Sheng H; Grocott HP; Bart RD; Pearlstein RD; Steffen RP; Warner DS
    Brain Res; 1999 May; 826(2):172-80. PubMed ID: 10224294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RSR13, a synthetic allosteric modifier of hemoglobin, improves myocardial recovery following hypothermic cardiopulmonary bypass.
    Kilgore KS; Shwartz CF; Gallagher MA; Steffen RP; Mosca RS; Bolling SF
    Circulation; 1999 Nov; 100(19 Suppl):II351-6. PubMed ID: 10567328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. RSR13, a synthetic modifier of hemoglobin-oxygen affinity, enhances the recovery of stunned myocardium in anesthetized dogs.
    Pagel PS; Hettrick DA; Montgomery MW; Kersten JR; Steffen RP; Warltier DC
    J Pharmacol Exp Ther; 1998 Apr; 285(1):1-8. PubMed ID: 9535987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RSR13, an allosteric effector of haemoglobin, and carbogen radiosensitize FSAII and SCCVII tumours in C3H mice.
    Khandelwal SR; Kavanagh BD; Lin PS; Truong QT; Lu J; Abraham DJ; Schmidt-Ullrich RK
    Br J Cancer; 1999 Feb; 79(5-6):814-20. PubMed ID: 10070874
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increasing P(50) does not improve DO(2CRIT) or systemic VO(2) in severe anemia.
    Eichelbrönner O; D'Almeida M; Sielenkämper A; Sibbald WJ; Chin-Yee IH
    Am J Physiol Heart Circ Physiol; 2002 Jul; 283(1):H92-101. PubMed ID: 12063279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RSR13, a synthetic allosteric modifier of hemoglobin, as an adjunct to radiotherapy: preliminary studies with EMT6 cells and tumors and normal tissues in mice.
    Rockwell S; Kelley M
    Radiat Oncol Investig; 1998; 6(5):199-208. PubMed ID: 9822166
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of a pharmacologically-induced shift of hemoglobin-oxygen dissociation on myocardial energetics during ischemia in patients with coronary artery disease.
    Najjar SS; Bottomley PA; Schulman SP; Waldron MM; Steffen RP; Gerstenblith G; Weiss RG
    J Cardiovasc Magn Reson; 2005; 7(4):657-66. PubMed ID: 16136855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allosteric modification of hemoglobin by RSR13 as a therapeutic strategy.
    Steffen RP; Liard JF; Gerber MJ; Hoffman SJ
    Adv Exp Med Biol; 2003; 530():249-59. PubMed ID: 14562722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.
    Shaw E; Scott C; Suh J; Kadish S; Stea B; Hackman J; Pearlman A; Murray K; Gaspar L; Mehta M; Curran W; Gerber M
    J Clin Oncol; 2003 Jun; 21(12):2364-71. PubMed ID: 12805339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preservation of canine myocardial high-energy phosphates during low-flow ischemia with modification of hemoglobin-oxygen affinity.
    Weiss RG; Mejia MA; Kass DA; DiPaula AF; Becker LC; Gerstenblith G; Chacko VP
    J Clin Invest; 1999 Mar; 103(5):739-46. PubMed ID: 10074492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of a synthetic allosteric modifier of hemoglobin oxygen affinity on outcome from global cerebral ischemia in the rat.
    Grocott HP; Bart RD; Sheng H; Miura Y; Steffen R; Pearlstein RD; Warner DS
    Stroke; 1998 Aug; 29(8):1650-5. PubMed ID: 9707208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The dose-dependent effect of RSR13, a synthetic allosteric modifier of hemoglobin, on physiological parameters and brain tissue oxygenation in rats.
    Grinberg OY; Miyake M; Hou H; Steffen RP; Swartz HM
    Adv Exp Med Biol; 2003; 530():287-96. PubMed ID: 14562725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of RSR13, an allosteric hemoglobin modifier, on oxygenation in murine tumors: an in vivo electron paramagnetic resonance oximetry and bold MRI study.
    Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Makki M; Demidenko E; Lu S; Steffen RP; Swartz HM
    Int J Radiat Oncol Biol Phys; 2004 Jul; 59(3):834-43. PubMed ID: 15183487
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of RSR13, a synthetic allosteric modifier of hemoglobin, on brain tissue pO2 (measured by EPR oximetry) following severe hemorrhagic shock in rats.
    Miyake M; Grinberg OY; Hou H; Steffen RP; Elkadi H; Swartz HM
    Adv Exp Med Biol; 2003; 530():319-29. PubMed ID: 14562728
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of tumor oxygenation and radiation response by the allosteric effector of hemoglobin, RSR13.
    Amorino GP; Lee H; Holburn GE; Paschal CB; Hercules SK; Shyr Y; Steffen RP; Choy H
    Radiat Res; 2001 Sep; 156(3):294-300. PubMed ID: 11500138
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.